Suppr
超能文献

A new RSV vaccine (mResvia) for adults ≥60 years old.

出版信息

Med Lett Drugs Ther. 2024 Oct 14;66(1713):166-168. doi: 10.58347/tml.2024.1713d.

DOI:10.58347/tml.2024.1713d

PMID:39382431

Abstract

摘要

相似文献

A new RSV vaccine (mResvia) for adults ≥60 years old.

Med Lett Drugs Ther. 2024 Oct 14;66(1713):166-168. doi: 10.58347/tml.2024.1713d.

In Brief: RSV vaccine (Arexvy) for ages 50-59.

Med Lett Drugs Ther. 2024 Jul 22;66(1707):113-114. doi: 10.58347/tml.2024.1707a.

Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.

Clin Infect Dis. 2024 May 15;78(5):1328-1335. doi: 10.1093/cid/ciad658.

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.

J Infect. 2019 May;78(5):382-392. doi: 10.1016/j.jinf.2019.02.003. Epub 2019 Feb 8.

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.

J Infect Dis. 2017 Jan 1;215(1):24-33. doi: 10.1093/infdis/jiw453. Epub 2016 Sep 29.

Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy.

Microb Pathog. 2013 Feb;55:9-15. doi: 10.1016/j.micpath.2012.11.013. Epub 2012 Dec 13.

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.

J Infect Dis. 2024 Jul 25;230(1):e102-e110. doi: 10.1093/infdis/jiad546.

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults.

J Infect. 2024 Aug;89(2):106211. doi: 10.1016/j.jinf.2024.106211. Epub 2024 Jun 26.

Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.

Hum Vaccin Immunother. 2017 May 4;13(5):1031-1039. doi: 10.1080/21645515.2016.1272743. Epub 2017 Jan 27.

Advances in and the potential of vaccines for respiratory syncytial virus.

Expert Rev Respir Med. 2013 Aug;7(4):411-27. doi: 10.1586/17476348.2013.814409.

引用本文的文献

Combining Intramuscular and Intranasal Immunization With the MF59-Adjuvanted Respiratory Syncytial Virus Pre-Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice.

MedComm (2020). 2025 Jul 15;6(8):e70301. doi: 10.1002/mco2.70301. eCollection 2025 Aug.

Recent advances in the prevention and treatment of respiratory syncytial virus disease.

J Gen Virol. 2025 Apr;106(4). doi: 10.1099/jgv.0.002095.

Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2.

Vaccines (Basel). 2024 Dec 22;12(12):1444. doi: 10.3390/vaccines12121444.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

A new RSV vaccine (mResvia) for adults ≥60 years old.

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译